FLVCR1 and ovarian cancer: FLVCR1-AS1 has been described as a new tumor suppressor as its impaired expression can lead to the development and spread of various cancers such as cholangiocarcinoma (CCA) [28], hepatocellular carcinoma (HCC) [29,30], gastric cancer (GC) [31], colorectal cancer (CRC) [32,33], glioma and glioblastoma (GBM) [34,35], non-small cell lung cancer (NSCLC) [36,37], ovarian cancer (OC) [38], breast cancer (BC) [39], and osteosarcoma (OS) [40], and in October 2021, was reported in pancreatic cancer (PC) [41].